Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-11-28
1999-08-31
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546199, C07D23156, C07D40112, A61K 31445
Patent
active
059454342
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
This invention relates to a new indazole derivative having a monocyclic amine, a pharmaceutically acceptable salt thereof and a process for the preparation thereof.
The invention further relates to a 5-HT.sub.4 receptor agonist, in particular, an agent for the treatment of digestive tract diseases which comprise as an active ingredient the indazole derivative or the salt thereof.
The invention furthermore relates to a method for the treatment of gastrointestinal disorders which comprises administering the indazole derivative or the salt thereof to the patients suffering from gastrointestinal disorders.
BACKGROUND ART
The abnormality in a gastrointestinal motor function by various causes such as chronic gastritis, gastrectomy, peptic ulcer, diabetes mellitus or scleroderma results in the reflux of gastric contents into the esophagus, delayed emptying of the contents and the depression of small and large intestinal functions.
This can lead to several gastrointestinal disorders including nausea, vomiting, heartburn, anorexia, abdominal distension, epigastric dysphoria, abdominaglia, constipation and further reflux esophagitis. One cause of the diseases such as irritable bowel syndrome and spurious ileus is considered to be the depression in gastrointestinal motility.
The agents for the treatment of these conditions and diseases include direct cholinergic agent (e.g. Aclatonium Napadisilate) or Dopamine antagonist (e.g. Domperidone).
However, it is known that these known agents have the problems of insufficent therapeutic effects and side effects including diarrhea and extrapyramidal syndrome.
The gastrointestinal motility is controlled by both sympathetic and parasympathetic nervous systems. In the parasympathetic nervous system, acetylcholine is one of the most important neurotransmitters participating in the control of gastrointestinal motility. The release of acetylcholine from the nerves in the nerve plexus of gastrointestinal tract may induce the contraction of gastrointestinal tract. Accordingly, the accelerated release of acetylcholine from the nerve plexus of gastrointestinal tract results in sthenia of gastrointestinal motility.
Recently, a 5-HT.sub.4 receptor was found in gastrointestinal tract. The 5-HT.sub.4 receptor was reported to control the release of acetylcholine 141-145, (1992)!. Thus, compounds acting on the 5-HT.sub.4 receptor in the gastrointestinal tract and promoting the release of acetylcholine may be a more effective gastrokinetic agent with less side effects.
On the other hand, WO 9303725 discloses that (1-butyl-4-piperidyl)methyl-1-methylindazole-3-carboxylate (Example 10) has a 5-HT.sub.4 receptor antagonist activity, and is of potential use in the treatment of diseases derived from 5-HT, diarrhea of irritable bowel syndrome due to the 5-HT activated intestinal nerve, cardiovascular disorders and CNS disorders. U.S. Pat. No. 3,145,215 discloses that hypotensive activity. However, it is not reported that those compounds have 5-HT.sub.4 receptor agonist activities and gastrointestinal prokinetic actions.
Aliment. Pharmacol. Ther., Vol. 6, 273-289, 1992 suggests that irritable bowel syndrome exists as two types, constipation-type and diarrhea-type irritable bowel syndromes and 5-HT.sub.4 receptor agonists are useful in the treatment of constipation-type irritable bowel syndrome, while Medicinal Research Reviews, Vol. 13, 633-662, 1993 suggests that 5-HT.sub.4 receptor antagonists are useful in the treatment of diarrhea-type irritable bowel syndrome.
WO 9312785 discloses that 5-HT.sub.4 receptor antagonists and agonists are of potential use in the treatment of conditions associated with bladder hypersensitivity and a poorly functioning bladder.
By elucidation of new compounds having a 5-HT.sub.4 receptor agonist activity, it has been demanded to develop a medicine based on such a mechanism of action that acts on the 5-HT.sub.4 receptor controlling the release of acetylcholine in the gastrointestinal nerve to promote the release of acetylcholine from the nerves in t
REFERENCES:
patent: 3145215 (1964-08-01), Kirchner et al.
patent: 5002948 (1991-03-01), Perregaard et al.
patent: 5017573 (1991-05-01), Kon et al.
patent: 5166341 (1992-11-01), Kon et al.
patent: 5654320 (1997-08-01), Catlow et al.
patent: 5684003 (1997-11-01), Kikuchi et al.
Joel Bockaert, John R. Fozard, Aline Dumuis and David E. Clarke, TiPS Reviews, vol. 13 (Apr. 1992). The 5-HT.sub.4 receptor: a place in the sun, pp. 141-145.
N.J. Talley. Aliment. Pharmacol. Ther,(Jan. 1992). Review article: 5-hydroxtryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications, pp. 273-289.
Anthony P.D.W. Ford and David E. Clarke, Medicinal Research Reviews, vol. 13, No. 6 (1993). The 5-HT.sub.4 Receptor, pp. 633-662.
Arai Takeo
Fukutomi Ryuta
Hagihara Koichiro
Kikuchi Haruhiko
Mino Setsuko
Nisshin Flour Milling Co. Ltd.
Rao Deepak R.
Raymond Richard L.
LandOfFree
Indazole derivatives having monocyclic amine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indazole derivatives having monocyclic amine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indazole derivatives having monocyclic amine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2426595